A Study of Q-1802 in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
Q-1802 is a bispecific antibody targeting both the tumor-specific antigen Claudin 18.2 and
the immune checkpoint PD-L1. This is a multi-center, single-arm, open-label design to
evaluate the safety and tolerance of Q-1802 in patients with advanced solid tumors, together
with an assessment of pharmacokinetic characteristics and efficacy. The study consisted of
two compartments: the dose-exploration stage and the dose-extension stage.